Liselotte Fierens, Sofie Coenen, Johan Joly, Tine Vanhoutvin, Els De Dycker, Delphine Bertrand, Eva Van Laer, Jens Penny, Jan Reumers, Patrick Verschueren, Petra De Haes, Paul De Munter, Marc Ferrante
{"title":"在电子病历中使用疫苗接种工具对免疫介导的炎症性疾病患者疫苗接种覆盖率的影响：一项前瞻性队列研究。","authors":"Liselotte Fierens, Sofie Coenen, Johan Joly, Tine Vanhoutvin, Els De Dycker, Delphine Bertrand, Eva Van Laer, Jens Penny, Jan Reumers, Patrick Verschueren, Petra De Haes, Paul De Munter, Marc Ferrante","doi":"10.1080/23744235.2024.2361795","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of immune-mediated inflammatory diseases (IMID) requires innovative management strategies, including effective vaccination. We aimed to assess the impact of an electronic medical record (EMR)-integrated vaccination tool on vaccination coverage among patients with inflammatory bowel diseases (IBD), rheumatological and dermatological conditions.</p><p><strong>Methods: </strong>A prospective observational study compared vaccination coverage before (2018) and after (2021) implementing the module. Vaccination data for influenza, pneumococcus, hepatitis B and tetanus, and potential predictors were collected from 1430 IMID patients (44.9% male, median age (interquartile range [IQR]) 54 (40-66) years, 789 with IBD, 604 with rheumatological and 37 with dermatological conditions). Data were analysed using McNemar, chi-square tests and multinominal logistic regression.</p><p><strong>Results: </strong>Significant increases in pneumococcus (56.6% to 73.1%, <i>p</i> < .001) and hepatitis B vaccination (62.2% to 75.9%, <i>p</i> < .001) were observed. Influenza vaccination rates increased among IBD (76.2% to 80.5%, <i>p</i> = .006) but remained stable overall (73.1% to 73.2%, <i>p</i> = 1.000). Tetanus vaccination rates decreased (71.5% to 55.0%, <i>p</i> < .001). The proportion of fully vaccinated patients (against influenza in the past year for patients >50 years old and/or under immunosuppressive therapy, against pneumococcus in the past 5 years for patients >65 years old and/or under immunosuppressive therapy and additionally against hepatitis B for IBD patients) rose from 41.3% to 54.8% (<i>p</i> < .001 all using McNemar). Factors associated with vaccinations included age, immunosuppressive therapy and education level.</p><p><strong>Conclusions: </strong>Increased vaccination coverage was measured after implementing the vaccination tool. The COVID19 pandemic and the 2018 measurement might have increased vaccination awareness. Education of patients and healthcare professionals remains crucial.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"870-879"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of implementing a vaccination tool in the electronic medical record on vaccination coverage of patients with immune-mediated inflammatory diseases: a prospective cohort study.\",\"authors\":\"Liselotte Fierens, Sofie Coenen, Johan Joly, Tine Vanhoutvin, Els De Dycker, Delphine Bertrand, Eva Van Laer, Jens Penny, Jan Reumers, Patrick Verschueren, Petra De Haes, Paul De Munter, Marc Ferrante\",\"doi\":\"10.1080/23744235.2024.2361795\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The rising incidence of immune-mediated inflammatory diseases (IMID) requires innovative management strategies, including effective vaccination. We aimed to assess the impact of an electronic medical record (EMR)-integrated vaccination tool on vaccination coverage among patients with inflammatory bowel diseases (IBD), rheumatological and dermatological conditions.</p><p><strong>Methods: </strong>A prospective observational study compared vaccination coverage before (2018) and after (2021) implementing the module. Vaccination data for influenza, pneumococcus, hepatitis B and tetanus, and potential predictors were collected from 1430 IMID patients (44.9% male, median age (interquartile range [IQR]) 54 (40-66) years, 789 with IBD, 604 with rheumatological and 37 with dermatological conditions). Data were analysed using McNemar, chi-square tests and multinominal logistic regression.</p><p><strong>Results: </strong>Significant increases in pneumococcus (56.6% to 73.1%, <i>p</i> < .001) and hepatitis B vaccination (62.2% to 75.9%, <i>p</i> < .001) were observed. Influenza vaccination rates increased among IBD (76.2% to 80.5%, <i>p</i> = .006) but remained stable overall (73.1% to 73.2%, <i>p</i> = 1.000). Tetanus vaccination rates decreased (71.5% to 55.0%, <i>p</i> < .001). The proportion of fully vaccinated patients (against influenza in the past year for patients >50 years old and/or under immunosuppressive therapy, against pneumococcus in the past 5 years for patients >65 years old and/or under immunosuppressive therapy and additionally against hepatitis B for IBD patients) rose from 41.3% to 54.8% (<i>p</i> < .001 all using McNemar). Factors associated with vaccinations included age, immunosuppressive therapy and education level.</p><p><strong>Conclusions: </strong>Increased vaccination coverage was measured after implementing the vaccination tool. The COVID19 pandemic and the 2018 measurement might have increased vaccination awareness. Education of patients and healthcare professionals remains crucial.</p>\",\"PeriodicalId\":73372,\"journal\":{\"name\":\"Infectious diseases (London, England)\",\"volume\":\" \",\"pages\":\"870-879\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23744235.2024.2361795\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23744235.2024.2361795","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Effects of implementing a vaccination tool in the electronic medical record on vaccination coverage of patients with immune-mediated inflammatory diseases: a prospective cohort study.
Background: The rising incidence of immune-mediated inflammatory diseases (IMID) requires innovative management strategies, including effective vaccination. We aimed to assess the impact of an electronic medical record (EMR)-integrated vaccination tool on vaccination coverage among patients with inflammatory bowel diseases (IBD), rheumatological and dermatological conditions.
Methods: A prospective observational study compared vaccination coverage before (2018) and after (2021) implementing the module. Vaccination data for influenza, pneumococcus, hepatitis B and tetanus, and potential predictors were collected from 1430 IMID patients (44.9% male, median age (interquartile range [IQR]) 54 (40-66) years, 789 with IBD, 604 with rheumatological and 37 with dermatological conditions). Data were analysed using McNemar, chi-square tests and multinominal logistic regression.
Results: Significant increases in pneumococcus (56.6% to 73.1%, p < .001) and hepatitis B vaccination (62.2% to 75.9%, p < .001) were observed. Influenza vaccination rates increased among IBD (76.2% to 80.5%, p = .006) but remained stable overall (73.1% to 73.2%, p = 1.000). Tetanus vaccination rates decreased (71.5% to 55.0%, p < .001). The proportion of fully vaccinated patients (against influenza in the past year for patients >50 years old and/or under immunosuppressive therapy, against pneumococcus in the past 5 years for patients >65 years old and/or under immunosuppressive therapy and additionally against hepatitis B for IBD patients) rose from 41.3% to 54.8% (p < .001 all using McNemar). Factors associated with vaccinations included age, immunosuppressive therapy and education level.
Conclusions: Increased vaccination coverage was measured after implementing the vaccination tool. The COVID19 pandemic and the 2018 measurement might have increased vaccination awareness. Education of patients and healthcare professionals remains crucial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
